文献速递新发突发、热带与寄生虫病

PRIMVAC疟疾疫苗联合Alhydrogel或GLA-SE佐剂预防妊娠期疟疾的首次人体随机双盲安慰剂对照研究

PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study.
PubMed 文献 · Lancet Infect Dis · 2020-02-04

PRIMVAC是一种基于VAR2CSA的妊娠期疟疾疫苗候选,旨在预防孕期恶性疟原虫感染的严重临床结局。本研究在法国未感染疟疾女性和布基纳法索自然暴露女性中评估了PRIMVAC联合Alhydrogel或GLA-SE佐剂的安全性和免疫原性。结果显示疫苗安全性可接受,所有接种者均产生抗体,GLA-SE佐剂倾向增强抗体反应,但异源VAR2CSA交叉反应有限。

要点

  • PRIMVAC联合Alhydrogel或GLA-SE佐剂安全性可接受,未发生疫苗相关严重不良事件。
  • 所有接种PRIMVAC的女性均发生血清转换,GLA-SE佐剂倾向提高抗体反应。
  • 交叉反应仅见于100μg剂量组,且对异源VAR2CSA变异体反应有限。

核心结论

  • PRIMVAC联合Alhydrogel或GLA-SE佐剂安全性可接受,具有免疫原性,可诱导与NF54-CSA感染红细胞表达的同源VAR2CSA变异体反应的功能性抗体。
  • 对异源VAR2CSA变异体的交叉反应有限,且仅在高剂量组观察到。

研究设计与样本

  • 首次人体、随机、双盲、安慰剂对照、剂量递增试验,分两阶段:法国1A期(18-35岁无疟疾暴露女性)和布基纳法索1B期(自然暴露于恶性疟原虫的未孕女性)。
  • 共纳入68名女性(法国18名,布基纳法索50名),按序贯队列接受20μg、50μg或100μg PRIMVAC肌肉注射(第0、28、56天),法国随机1:1分配至Alhydrogel或GLA-SE佐剂组,布基纳法索随机2:2:1分配至Alhydrogel、GLA-SE或安慰剂组。
  • 主要终点为至第35天发生任何3级或以上不良事件的比例。

主要发现

  • 未发生与疫苗相关的严重不良事件。
  • 所有接种PRIMVAC的女性(n=57)均发生血清转换,抗体滴度随每剂次增加。

关键数值与推荐

  • 主要终点:至第35天发生任何3级或以上不良事件的比例。
  • 免疫原性评估:抗体滴度、血清转换率、抗体持续时间及与同源/异源VAR2CSA变异体的反应性。

临床怎么用

  • PRIMVAC疫苗安全性可接受且具有免疫原性,支持进一步开发用于预防妊娠期疟疾。
  • GLA-SE佐剂可能优于Alhydrogel,但需进一步研究确认。
  • 对异源VAR2CSA变异体交叉反应有限,提示可能需要调整免疫方案、抗原剂量或联合其他VAR2CSA疫苗以提高交叉反应性。

局限性

  • 交叉反应仅在高剂量组观察到,且对异源变异体反应有限。
  • 研究仅在法国和布基纳法索进行,样本量较小。
  • 未评估疫苗对妊娠期疟疾临床结局的实际保护效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PRIMVAC is a VAR2CSA-derived placental malaria vaccine candidate aiming to prevent serious clinical outcomes of Plasmodium falciparum infection during pregnancy. We assessed the safety and immunogenicity of PRIMVAC adjuvanted with Alhydrogel or glucopyranosyl lipid adjuvant in stable emulsion (GLA-SE) in French and Burkinabe women who were not pregnant. METHODS: This first-in-human, randomised, double-blind, placebo-controlled, dose escalation trial was done in two staggered phases, a phase 1A trial in 18-35-year-old women who were malaria naive in a hospital in France and a subsequent phase 1B trial in women who were naturally exposed to P falciparum and nulligravid in the clinical site of a research centre in Burkina Faso. Volunteers were recruited into four sequential cohorts receiving PRIMVAC intramuscularly at day 0, 28, and 56: two cohorts in France receiving 20 μg or 50 μg of PRIMVAC and then two in Burkina Faso receiving 50 μg or 100 μg of PRIMVAC. Volunteers were randomly assigned (1:1) to two groups (PRIMVAC adjuvanted with either Alhydrogel or GLA-SE) in France and randomly assigned (2:2:1) to three groups (PRIMVAC adjuvanted with either Alhydrogel, GLA-SE, or placebo) in Burkina Faso. Randomisation was centralised, using stratification by cohort and blocks of variable size, and syringes were masked by opaque labels. The primary endpoint was the proportion of participants with any grade 3 or higher adverse reaction to vaccination up until day 35. Safety at later time points as well as humoral and cellular immunogenicity were assessed in secondary endpoints. This trial is registered with ClinicalTrials.gov, NCT02658253. FINDINGS: Between April 19, 2016, and July 13, 2017, 68 women (18 in France, 50 in Burkina Faso) of 101 assessed for eligibility were included. No serious adverse event related to the vaccine occurred. PRIMVAC antibody titres increased with each dose and seroconversion was observed in all women vaccinated with PRIMVAC (n=57). PRIMVAC antibody titres reached a peak (geometric mean 11 843·0, optical density [OD] 1·0, 95% CI 7559·8-18 552·9 with 100 μg dose and GLA-SE) 1 week after the third vaccination (day 63). Compared with Alhydrogel, GLA-SE tended to improve the PRIMVAC antibody response (geometric mean 2163·5, OD 1·0, 95% CI 1315·7-3557·7 with 100 μg dose and Alhydrogel at day 63). 1 year after the last vaccination, 20 (71%) of 28 women who were vaccinated with PRIMVAC/Alhydrogel and 26 (93%) of 28 women who were vaccinated with PRIMVAC/GLA-SE still had anti-PRIMVAC antibodies, although antibody magnitude was markedly lower (452·4, OD 1·0, 95% CI 321·8-636·1 with 100 μg dose and GLA-SE). These antibodies reacted with native homologous VAR2CSA expressed by NF54-CSA infected erythrocytes (fold change from baseline at day 63 with 100 μg dose and GLA-SE: 10·74, 95% CI 8·36-13·79). Limited cross-recognition, restricted to sera collected from women that received the 100 μg PRIMVAC dose, was observed against heterologous VAR2CSA variants expressed by FCR3-CSA (fold change from baseline at day 63: 1·49, 95% CI 1·19-1·88) and 7G8-CSA infected erythrocytes (1·2, 1·08-1·34). INTERPRETATION: PRIMVAC adjuvanted with Alhydrogel or GLA-SE had an acceptable safety profile, was immunogenic, and induced functional antibodies reacting with the homologous VAR2CSA variant expressed by NF54-CSA infected erythrocytes. Cross-reactivity against heterologous VAR2CSA variants was limited and only observed in the higher dose group. An alternate schedule of immunisation, antigen dose, and combinations with other VAR2CSA-based vaccines are envisaged to improve the cross-reactivity against heterologous VAR2CSA variants. FUNDING: Bundesministerium für Bildung und Forschung, through Kreditanstalt für Wiederaufbau, Germany; Inserm, and Institut National de Transfusion Sanguine, France; Irish Aid, Department of Foreign Affairs and Trade, Ireland.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Sirima SB, Richert L, Chêne A, et al. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study. Lancet Infect Dis. 2020. PMID: 32032566. doi:10.1016/S1473-3099(19)30739-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。